5′ ALK Amplification in Neuroblastoma: A Case Report

Abstract

Neuroblastoma is the most common cancer in infants younger than 12 months of age, occurring with an incidence of 1 in 100,000 children. The clinical outcome of neuroblastoma ranges from spontaneous regression to treatment-resistant progression and/or metastasis, and accounts for 8–10% of childhood cancer deaths. Segmental chromosomal aberrations, as well as <i>MYCN</i> and <i>ALK</i> amplification, are among factors contributing to an unfavorable genomic profile and high-risk disease classification. Here, we describe a 5-year-old male who presented with a large right renal neuroblastoma tumor having lung and liver metastases. Fluorescence in situ hybridization analysis indicated the presence of &#x3e;20 copies of the 5′ region of the <i>ALK</i> gene in 26% of cells examined. Subsequent copy number assessment did not confirm <i>ALK</i> amplification, but revealed a gain of exons 2–5 of <i>ALK</i>, consistent with increased copy number for the 5′ region of the <i>ALK</i> gene. Subsequent array analysis showed the presence of other unfavorable prognostic genomic features, including segmental gain of the 17q region and amplification of the long arm of chromosome 12 harboring <i>CDK4</i> and <i>MDM2,</i> both reported to be poor prognostic indicators in patients with atypical clinical features in neuroblastoma. Taken together, this report illustrates the importance of careful interpretation of aberrant FISH findings and subsequent use of orthogonal methods to clarify the presence of genomic alterations to successfully determine potential treatment targets.